Shire, 2 generics-makers settle litigation tied to Intuniv

04/26/2013 | Reuters

Shire settled all litigation with Watson Pharma and Actavis regarding its attention-deficit/hyperactivity disorder treatment Intuniv. Under the settlement, Actavis can produce and market its generic copy of the drug in the U.S. starting Dec. 1, 2014, while Watson could follow with its version 181 days after the release of Actavis' version.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX